Schering Corporation

Vilas H Dahanukar

Ilia A Zavialov

Craig D Boyle

Kevin Joseph Klopfer

Dinesh Gala

Doris P Schumacher

Jeffrey Manning Eckert

Hoa N Nguyen

Cecilia A Orr

Funcheng Zhang

Jeffrey M Skell

Albert W Buchholz, Jr

Brian Lucas

Crystalline polymorphs of 1-ethyl-3,7-dihydro-8-[(1R,2R) -(hydroxycyclopentyl)amino]-3-(2-hydroxyethyl)-7-[(3-bromo-4-methoxyphenyl)methyl]-1H-Purine-2,6-dione in Form 1 and Form 2, which exhibit x-ray powder diffraction profiles substantially the same as those shown in FIGS.and, respectively, and which exhibit differential scanning calorimtery profiles substantially the same as those shown in FIGS.and, respectively, and are represented by the formula:  Pharmaceutical compositions comprising the polymorph Form 1 or 2 of Compound 13 and at least one excipient or carrier, and methods of using the polymorph Form 1 or 2 of Compound 13 to treat a variety of physiological disorders, such as erectile dysfunction.

Xanthine phosphodiesterase V inhibitor polymorphs

In one embodiment, the present invention describes the synthesis of a compound of formulaand intermediates therefor.

Process for synthesis of D1 receptor antagonists

Growing community of inventors

Edison, NJ, United States of America

Vilas H Dahanukar